ANTHELIOS 40

LOE Approaching

avobenzone; ecamsule; octocrylene; titanium dioxide

NDATOPICALCREAM

Approved

Mar 2008

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Data completeness

2/8 — Basic

ANTHELIOS 40 (avobenzone; ecamsule; octocrylene; titanium dioxide). Approved for sunburn if used, decreases the risk of skin cancer, early skin aging caused by the sun. First approved in 2008.

Drug data last refreshed 5d ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (3)

sunburn if used decreases the risk of skin cancer early skin aging caused by the sun

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.